DENOSUMAB VERSUS ZOLEDRONIC ACID FOR THE PREVENTION OF SKELETAL-RELATED EVENTS IN PATIENTS WITH BONE METASTASES SECONDARY TO SOLID TUMOURS: AN INTEGRATED ANALYSIS OF THREE PHASE 3 STUDIES

被引：1
|
作者：
Stopeck, A. T. [1 ]
Richardson, G. [2 ]
Siena, S. [3 ]
Lipton, A. [4 ]
Brown, J. [5 ]
Fizazi, K. [6 ]
Henry, D. [7 ]
Saad, F. [8 ]
Ke, C. [9 ]
Braun, A. [9 ]
机构：
[1] Univ Arizona, Arizona Canc Ctr, Tucson, AZ USA
[2] Cabrini Hosp, Malvern, Vic, Australia
[3] Osped Niguarda Ca Granda, Milan, Italy
[4] Penn State Univ, Milton S Hershey Med Ctr, Hershey, PA 17033 USA
[5] Canc Res, UK Clin Ctr, Leeds, W Yorkshire, England
[6] Univ Paris 11, Inst Gustave Roussy, Villejuif, France
[7] Joan Karnell Canc Ctr, Philadelphia, PA USA
[8] Univ Montreal, Ctr Hosp, Montreal, PQ, Canada
[9] Amgen Inc, Thousand Oaks, CA 91320 USA
来源：
EUROPEAN JOURNAL OF CANCER | 2012年 / 48卷
关键词：
D O I：
10.1016/j.ejca.2012.02.030
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S8 / S8
页数：1
相关论文
共 50 条
  • [41] Cost-effectiveness of denosumab versus zoledronic acid for preventing skeletal-related events in the Czech Republic
    Cristino, Joaquim
    Finek, Jindrich
    Jandova, Petra
    Kolek, Martin
    Pasztor, Balint
    Giannopoulou, Christina
    Qian, Yi
    Brezina, Tomas
    Lothgren, Mickael
    JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (08) : 799 - 812
  • [42] Incidence of hypocalcemia in patients receiving denosumab for prevention of skeletal-related events in bone metastasis
    Yerram, Prakirthi
    Kansagra, Shraddha
    Abdelghany, Osama
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2017, 23 (03) : 179 - 184
  • [43] RETROSPECTIVE DATABASE ANALYSIS OF THE EFFECT OF ZOLEDRONIC ACID ON SKELETAL-RELATED EVENTS IN MEN WITH PROSTATE CANCER AND BONE METASTASES
    Henk, H. J.
    Kaura, S.
    VALUE IN HEALTH, 2010, 13 (07) : A254 - A254
  • [44] Cost-effectiveness of denosumab (Dmab) versus zoledronic acid (ZA) for prevention of skeletal-related events (SREs) in patients (pts) with castrate-resistant prostate cancer (CRPC) and bone metastases (BM)
    Rader, Michael E.
    Danese, Mark
    Cong, Ze
    Halperin, Marc
    Qian, Yi
    Goessl, Carsten Dietrich
    Chung, Karen
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [45] CECOG experts' recommendations on the use of denosumab in the prevention of skeletal-related events in bone metastases of lung cancer
    Hilbe W.
    Abacioglu U.
    Aebersold D.M.
    Bachouchi M.
    Brodowicz T.
    Gaafar R.
    Holzer G.
    Mohn-Staudner A.
    Kalev D.
    Kalinka-Warzocha E.
    Kovac V.
    Siano M.
    Yumuk F.
    Tamasi L.
    memo - Magazine of European Medical Oncology, 2013, 6 (2) : 75 - 82
  • [46] Interpreting results from oncology clinical trials: a comparison of denosumab to zoledronic acid for the prevention of skeletal-related events in cancer patients
    Dranitsaris, George
    Hatzimichael, Eleftheria
    SUPPORTIVE CARE IN CANCER, 2012, 20 (07) : 1353 - 1360
  • [47] Bisphosphonates in prevention and control of skeletal-related events in cancer patients with bone metastases
    Drosik, Kazimierz
    Krzakowski, Maciej
    Jarosz, Jerzy
    Kraj, Maria
    Krzemieniecki, Krzysztof
    Pienkowski, Tadeusz
    Utracka-Hutka, Beata
    Jassem, Jacek
    Szczylik, Cezary
    Wojtukiewicz, Marek
    Ziobro, Marek
    ONCOLOGY IN CLINICAL PRACTICE, 2006, 2 (04): : 152 - 164
  • [48] Health resource utilisation associated with skeletal-related events in patients with bone metastases secondary to solid tumours: regional comparisons in an observational study
    Duran, I.
    Fink, M. G.
    Bahl, A.
    Hoefeler, H.
    Mahmood, A.
    Lueftner, D.
    Ghazal, H.
    Wei, R.
    Chung, K. C.
    Hechmati, G.
    Green, J.
    Atchison, C.
    EUROPEAN JOURNAL OF CANCER CARE, 2017, 26 (06)
  • [49] Interpreting results from oncology clinical trials: a comparison of denosumab to zoledronic acid for the prevention of skeletal-related events in cancer patients
    George Dranitsaris
    Eleftheria Hatzimichael
    Supportive Care in Cancer, 2012, 20 : 1353 - 1360
  • [50] Meta-analysis comparing denosumab and zoledronic acid for treatment of bone metastases in patients with advanced solid tumours
    Zheng, G. Z.
    Chang, B.
    Lin, F. X.
    Xie, D.
    Hu, Q. X.
    Yu, G. Y.
    Du, S. X.
    Li, X. D.
    EUROPEAN JOURNAL OF CANCER CARE, 2017, 26 (06)
12345